Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Stocks to Watch for June 10: Bharti Airtel, Indigo, Ajanta Pharma, OMC stocks and more
Bharti Airtel gains relief after the Bombay High Court quashed OTSC demands, while IndiGo remains in focus following a 10% hike in aviation turbine fuel prices. Ajanta Pharma sees a promoter stake sale via a block deal, the government expands NLC India's OFS, and Dixon Technologies plans a telecom manufacturing joint venture with Gemtek. Here are the key stocks to watch ahead of Wednesday's trading session.
Haleon to invest Rs 2,000 crore to set up first India plant
Haleon is investing Rs 2,000 crore to build its first manufacturing plant in Pithampur, India. This move sharpens its focus on India, a fast-growing consumer healthcare market. The plant will produce oral-health products, including Sensodyne. It aims to reach one billion more consumers by 2030, with 300 million in India. The facility will also cater to export markets.
Nifty 50, Sensex May Open Muted Ahead of RBI Policy; Titan, Aurobindo Pharma, Groww in Focus - Dalal Street Investment Journal
Nifty 50, Sensex May Open Muted Ahead of RBI Policy; Titan, Aurobindo Pharma, Groww in FocusDalal Street Investment Journal
Stocks in news: Rajesh Exports, Lenskart, Suzlon Energy, Aurobindo Pharma, Tata Motors
Indian markets saw volatility and closed lower on Wednesday. Key companies are in focus due to significant developments. SoftBank reduced its stake in Lenskart. Sebi issued an interim order against Rajesh Exports. Tata Motors revised its Avinya EV strategy. Suzlon Energy is diversifying into battery storage. RIL's subsidiary signed MoUs with the Haryana Government.
Alkem Labs shares in focus as Goldman, Morgan Stanley, others purchase stake in Rs 930-crore block deal
Shares of Alkem Laboratories will be in focus after block deals worth around Rs 930 crore saw 17.88 lakh shares traded at Rs 5,200 apiece on Tuesday. Promoter-linked entities offloaded their stake, while domestic mutual funds and foreign institutional investors emerged as key buyers, signalling strong institutional participation. The company also launched semaglutide pre-filled syringes in India.
Stocks to Watch, June 3: Alkem Labs, Dhanuka Agritech, Paytm, Canara Bank
Stocks to Watch today, June 3: Infosys, Alkem Labs, Paytm among others in focus; here's why
Stocks in news: Alkem Labs, Vedanta, Canara Bank, NHPC, Adani Ports
Markets closed higher on weekly expiry day despite volatility, with Nifty showing signs of recovery but facing resistance around 23,800-24,000. Key stocks like Alkem Labs, Vedanta, Canara Bank, NHPC, and Adani Ports are in focus due to significant corporate developments including block deals, ED visits, capital raising plans, oversubscribed OFS, and strong cargo volumes.
After a dull Q4, Glenmark Pharma needs a booster shot to grow
Investors are shifting their focus to core operational execution as the drugmaker looks past one-off licensing gains to drive its FY27 growth.
Sensex Today | Stock Market LIVE Updates: GIFT Nifty extends losses to 200 points; Lenskart in focus
Sensex Today | Stock Market LIVE Updates: The bulls may take comfort from the fact that all recent selling has seen a reversal around this 23,250 - 23,350 range. A break of that level risks further downside for the index. Same is the case with the Nifty Bank, which had another 1,000-point range trading day on Monday.
Alkem Labs shares in focus as sellers look to offload 1.5% stake via block deal
The term sheet also specifies a 90-day lock-up period on any further sale of shares by the sellers.
Coinbase plans retail launch in India comeback, to deepen crypto exposure
The focus on India as a market comes as the company continues to see high adoption even as regulations around crypto are yet to take shape
Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study
Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, even in patients who previously received Novartis' Pluvicto. Response rates were higher in patients without prior Pluvicto treatment. Larger trials are planned to assess side effects. Novartis is increasing its focus on radioligand therapies.